NO-dependent S-nitrosylation of ICAM-1 modulates Src signaling to restore endothelial barrier function in senescence

Hypothesis

Restoring nitric oxide (NO) bioavailability in senescent endothelial cells promotes S‑nitrosylation of ICAM‑1 at a specific cysteine residue, which diminishes Src kinase binding and shifts ICAM‑1 signaling from a pro‑inflammatory, junction‑disrupting mode to a pro‑resolving, barrier‑protective state.

Mechanistic Model

1. BH4 depletion and eNOS uncoupling reduce NO production and increase superoxide, perpetuating senescence [1].
2. NO deficiency leaves ICAM‑1 cysteine residues in a reduced state, favoring Src association via its SH2 domain [2]. Src activation phosphorylates downstream targets that trigger VE‑cadherin internalization and junctional loosening.
3. Increased NO (via BH4 salvage or direct donors) leads to S‑nitrosylation of ICAM‑1 Cys‑xxx, sterically hindering Src docking and attenuating its kinase activity.
4. Reduced Src signaling preserves VE‑cadherin at the membrane, limits leukocyte transmigration portals at tricellular junctions, and allows NO‑mediated suppression of oxidative stress, creating a positive feedback loop that stabilizes the non‑senescent phenotype.

Testable Predictions

• Senescent endothelial cells treated with BH4 precursors (e.g., sepiapterin) or NO donors will show increased S‑nitrosylated ICAM‑1 detectable by biotin‑switch assay.
• This modification will correlate with decreased Src‑ICAM‑1 co‑immunoprecipitation and lower Src autophosphorylation (Y416).
• Barrier integrity, measured by transendothelial electrical resistance (TEER) and FITC‑dextran flux, will improve concomitant with reduced ICAM‑1‑dependent leukocyte adhesion under TNF‑α stimulation.
• Mutating the putative nitrosylation cysteine to serine will abolish the protective effect of NO donors, confirming site‑specific action.

Experimental Approach

1. Cell model: Human umbilical vein endothelial cells (HUVECs) induced to replicative senescence via prolonged passaging or doxorubicin treatment.
2. Interventions: (a) Sepiapterin (BH4 precursor), (b) NO donor (DEA‑NONOate), (c) Combination, (d) Vehicle control.
3. Readouts:
   • BH4/BH2 ratios by HPLC.
   • NO production via DAF‑FM fluorescence.
   • ICAM‑1 S‑nitrosylation using biotin‑switch followed by Western blot.
   • Src‑ICAM‑1 interaction by co‑IP.
   • Src activity (p‑Y416 Src) and downstream p‑FAK/p‑paxillin.
   • VE‑cadherin membrane localization by immunofluorescence.
   • TEER and paracellular permeability assays.
   • Leukocyte adhesion/transmigration using HL‑60 cells under flow.
4. Validation: Generate ICAM‑1 C→S mutant via CRISPR‑Cas9; repeat NO donor treatments to assess loss of barrier rescue.

Potential Impact

If confirmed, this hypothesis identifies a redox‑sensitive switch that couples NO bioavailability to ICAM‑1 signaling quality, offering a dual‑target strategy: augment BH4/NO while preserving ICAM‑1’s homeostatic functions. Such insight could refine senolytics or vasoactive therapies for age‑related vascular dysfunction.